Upload
others
View
16
Download
2
Embed Size (px)
Citation preview
Autoimmune
Pancreatitis
Dimitrios P Bogdanos Professor of Immunopathology
When to suspect How to confirm
How/when to treat
2008-2013 I have received in the past Lecture Honoraria, Consultation Fees, Expert
Panel Fees, Accommodation/Travel Expenses Coverage
INOVA, EUROIMMUN, Generic Assays, FALK, BIORAD,
(King’s College Hospital Charitable Trust) Part of travel/accommodation expenses are covered by the Organizers
I do not have shares or any other relevant financial or other relationship with a commercial organization that could influence the content of my
presentation
ALL FEES OR HONORIA SUPPORT MY FELLOWS’S RESEARCH INITIATIVES/CONFERENCE TRAVEL EXPENSES
Disclosure statement
EUROPE AID Biorad CyBio Diarect Euclone EUROIMMUN Generic Assays InnoVision Invitrogen- MabTech Mardx Meridian LS Menarini Miltenyi Molecular Probes PeproTech Pharmacia Roche
I have received diagnostic reagents free of charge and/ or participated in collaborative projects
AMERICA Gilead INOVA IMCCO Virusys
JAPAN MBL
Dis
clo
sure
sta
tem
en
t II
Autoimmune Pancreatitis: Current Status
pubmed - autoimmune pancreatitis pubmed - autoimmune pancreatitis
year count
2013 152
2012 196
2011 174
2010 164
2009 166
2008 154
2007 125
2006 96
2005 97
2004 60
2003 49
2002 36
2001 37
2000 23
1999 17
1998 11
1997 14
1996 11
1995 11
1994 5
1993 12
1992 8
1991 1
1990 5
1989 3
1988 12
1987 4
1986 8
1985 7
1984 8
1983 4
1982 2
1981 2
1980 4
1979 1
1978 4
1977 1
1976 2
1975 1
1974 1
1973 4
1972 4
1971 1
1970 3
1969 2
1968 2
1967 5
1966 2
Autoimmune Pancreatitis: Current Status
Figure 1 Key historical events in chronic pancreatitis.
Anil K. Rustgi
A Historical Perspective on Clinical Advances in Pancreatic Diseases
Gastroenterology Volume 144, Issue 6 2013 1249 - 1251
http://dx.doi.org/10.1053/j.gastro.2013.03.010
Chronic pancreatitis is a progressive inflammatory disease of the pancreas with irreversible damage of pancreatic tissue exocrine and endocrine insufficiency
Incidence of Chronic Pancreatitis
Switzerland 1.2/100 000/year
Poland 4.0/100 000/year
Germany 7.4/100 000/year
Czech Rep. 7.9/100 000/year
Hungary 8.0/100 000/year
Denmark 10.0/100 000/year
Sweden 10.0/100 000/year
Finland 23.0/100 000/year
United States 5.7-7.6/100 000/year
-oxic-metabolic -diopathic -enetic -utoimmune -ecurrent acute pancreatitis -bstructive
Etemed, Whitcomb, 2001
TIGARO Classification
T I GAR O
Tigar-O Classification System
Genetic
Hereditary pancreatitis
Cationic trypsinogen
PRSS1
PRSS2
CFTR mutations
SPINK1 mutations
Autoimmune
Autoimmune pancreatitis
Inflammatory bowel disease
Primary biliary cirrhosis
Year Reference Reported findings
1961 Sarles et al10
Reported a form of idiopathic chronic pancreatitis associated with
hypergammaglobulinaemia; suspected an autoimmune
mechanism
1991 Kawaguchi et al11 Described the histopathological pattern of what was later called
type 1 AIP (‘lymphoplasmacytic sclerosing pancreatitis (LPSP)’)
1995 Yoshida et al3 Coined the term ‘autoimmune pancreatitis’. Described all the major
clinical features of what was later called type 1 AIP
2001 Hamano et al12 Reported that elevated serum IgG4 levels were highly specific and
sensitive for the diagnosis of AIP
2002 Japan Pancreas
Society (JPS)13 First JPS diagnostic criteria for AIP
2003 Kamisawa et al14
Proposed that AIP was a systemic disease based on the findings
that the pancreas and other involved organs have abundant
infiltration with IgG4+ve plasma cells
2003 Notohara et al15
Reported two histological patterns in patients with ‘idiopathic
chronic pancreatitis with lymphoplasmacytic infiltration
sometimes called autoimmune pancreatitis’ (a) LPSP and
(b) idiopathic duct centric pancreatitis (IDCP)
2004 Kamisawa et al16 Japanese experience of steroid therapy in AIP
2006 Chari et al17 HISORt criteria for AIP published
2006 Kim et al18 Korean criteria for AIP published
2008 Ghazale et al19 First report of use of azathioprine in AIP
2008 Topazian et al20 First report of use of rituximab in AIP
2008 Moon et al21 Steroid trial to distinguish AIP from pancreatic cancer
2009 Chari et al22 Revised HISORt criteria
2010 Chari et al9 International consensus on classification of AIP into type 1 and
type 2
2011 Shimosegawa et
al23 International consensus diagnostic criteria
2012 Hart et al24 Proposed an algorithm for managing AIP using steroids,
immunomodulators and rituximab
HISORt CRITERIAS OF AIP Category Criteria
A. Histology 1. Diagnostic (any one): a) Pancreatic histology showing periductal lymphoplasmacytic infiltrate with obliterative hlebitis (LPSP) b) Lymphoplasmacytic infiltrate with abundant (>10 cells/hpf) IgG4 positive cells in the pancreas 2. Supportive (any one) a) Lymphoplasmacytic infiltrate with abundant (>10 cells/hpf) IgG4 positive cells in involved extra-pancreatic organ b) Lymphoplasmacytic infiltrate with fibrosis in the pancreas
B. Imaging Typical imaging features: 1. CT/MR: diffusely enlarged gland with delayed (rim) endhancement 2. ERCP: Diffusely irregular, attenuated main pancreatic duct
Atypical Imaging Features: Pancreatitis, focal pancreatic mass, focal pancreatic duct stricture, pancreatic atrophy, pancreatic calcification
C. Serology Elevated serum IgG4 level (normal 8-140 mg/dl)
D. Other Organ involvement
Hilar/intrahepatic biliary strictures, persistent distal biliary stricture, Parotid/lacrimal gland involvement, Mediastinal lymphadenopathy, Retroperitoneal fibrosis
E. Response to steroid therapy
Resolution/marked improvement of pancreatic/extrapancreatic manifestation with steroid therapy
Definition
Chronic pancreatitis caused by autoimmune inflammatory process
Lymphocyte infiltration
Fibrosis of pancreas
Organ dysfunction
Epidemiology
Rare
Increase in number of reported cases past 10 years
Prevalence and incidence not yet determined—possibly between 5-6% of all cases of chronic pancreatitis
May have increased prevalence in Japan
Twice as common in men as in women
Most patients are > 50 years old
The annual number of Japanese patients with type 1 Autoimmune Pancreatitis (AIP) is 0.71 per 100,000, which accounts for 2% of patients with chronic pancreatitis
Nishimori J Gastroenterol 2007
Incidence of autoimmune pancreatitis
Japan 21/451 4,6% Yoshida et al. Dig.Dis.Sci. 1995
Korea 17/315 5,4% Kim et al. Am.J.Gastroenterol. 2004
Italy 23/383 6,0% Parson et al. Pancreas 2003
Czech Rep. 9/185 4,8% Dite et al Best Practice and Res Clin. Gastroent., 2008
Sex ang age onset of autoimmune pancreatitis
Nishimori I. et al., Gastroent., 2007
Clinical Features
Unusual to present w/ severe abdominal pain
Usually mild, acute recurrent pancreatitis
Abdominal pain, weight loss, jaundice, obstructive pattern of LFTs
Biliary and pancreatic duct strictures
Pancreatic mass—can be confused with pancreatic carcinoma or lymphoma
Features of other autoimmune diseases
Clinical Features
Kamisawa et al Gut 2013
AUTOIMMUNE PANCREATITIS
23,0% FOCAL FORM (LIKE MALIGNANT LESION)
DIFFUSE FORM 77,0% (LIKE ACUTE PANCREATITIS)
Physical Examination
Imaging
MRI: sausage-shaped enlargement of pancreas, minimal fat stranding, peripheral rim of hypoattenuation “halo”
Similar lesions seen on CT
Can also see focal pancreatic involvement, usually in the head of pancreas
Imaging
EUS: diffusely hypoechoic, enlarged pancreas
ERCP: narrowed main and dorsal pancreatic duct, diffuse, irregular narrowing of duct, focal stricture of duct, irregular narrowing of intrahepatic ducts, lesion in pancreatic head can be seen
May not be able to distinguish between malignancy and autoimmune pancreatitis based on these results
CT Scan
CT scan of a patient with autoimmune pancreatitis. The head of the pancreas is enlarged (long arrow) and the common bile (small arrow) is dilated
Pancreatic Head Mass CT scan
showing low
attenuation, ill-defined
lesion in the pancreatic head with enhancing
mural thickening
at the gallbladder
fundus
ERCP
Endoscopic retrograde cholangio- pancreatography in a patient with autoimmune pancreatitis. The left panel shows a stricture in the common bile duct due to the surrounding enlarged pancreas. The right panel shows a stent that has been inserted across the narrowed segment
Endoscopic ultrasonographic image showing fine-needle aspiration of a hypoechoic mass
(arrow) in the head of the pancreas.
LAW R et al. Cleveland Clinic Journal of Medicine
2009;76:607-615
Dual-phase helical computed tomography shows focal enlargement of the pancreatic tail
(arrow) in a patient with autoimmune pancreatitis
LAW R et al. Cleveland Clinic Journal of Medicine
2009;76:607-615
©2009 by Cleveland Clinic
Gross Specimen: The real thing
Surgical specimen in a patient who underwent resection for autoimmune pancreatitis
Fig. 2 Gross pathology specimen of AIP in the head of the pancreas. Note the small narrowed pancreatic duct.
David G. Forcione , William R. Brugge
New kid on the block? Autoimmune pancreatitis
Best Practice & Research Clinical Gastroenterology Volume 24, Issue 4 2010 361 - 378
http://dx.doi.org/10.1016/j.bpg.2010.04.002
Pathology
Diffusely indurated and firm pancreas on gross exam
Focal mass can be found in a subset of patients
Collar-like periductal infiltrate composed of lymphocytes and plasma cells
Can also involve gallbladder, bile ducts, kidney, lung, and salivary glands with dense lymphocytic infiltrate
Histology of autoimmune pancreatitis
DG Forcione Res Clin Gastroenterol 2010
Note the presence of lympho-plasmacystic cellular infiltrates
Autoimmune pancreatitis with intense and destructive fibroinflammatory replacement of
normal pancreatic parenchyma.
LAW R et al. Cleveland Clinic Journal of Medicine
2009;76:607-615
IgG4 immunohistochemistry in autoimmune pancreatitis showing more than 30 stained plasma cells (brown cells)
per 400X high-power field (dimethylaminoazobenzine chromagen and hematoxylin counterstain).
LAW R et al. Cleveland Clinic Journal of Medicine
2009;76:607-615
IgG4: serological marker as
well as histological marker
Nat Clin Pract Gastroenterol Hepatol
Overview of published series on the use of serological markers for the diagnosis of autoimmune pancreatitis
Scattergram of IgG4 values for patients with autoimmune pancreatitis and related diseases. PBC primary biliary cirrhosis, PSC primary sclerosing cholangitis
Kawa et al., Gastroent., 2007
Antibodies in patients with AIP
%
Okazaki et al. J. Gastroent. 2001
Zen J Hepatol 2013
Zen J Hepatol 2013
Treatment
Can respond dramatically to corticosteroids—optimal dose and duration not yet established
Possible approach: prednisone 40 mg daily for 4-6 weeks, followed by taper of 5 mg/week
Patients usually followed immunologically and by CT scan while on therapy
Recurrence of autoimmune pancreatitis
Takayama et al (Amer.J.Gastroent. 2004) 42(11) 26%
Wakabyashi et al.(Pancreas 2005) 36( 6) 17%
Zamboni et al. Wirchow Arch. 2004) 22( 5) 23%
Kim et al. (A.J. Gastroent. 2004) 17( 1) 6%
Ramisawa et al. (J.Gastroenterol. 2007) 32( 2) 6%
COMPARISON OF SUBJECTS WITH AIP AND PANCREATIC CANCER
AIP (N=45) Pacreatic Cancer
(N=135)
P Value
Gender, % male 37/45 (82%) 79/135 (59%) 0,004
Mean age ± SEM 59,6 ± 2,5 67,3 ± 1,1 0,001
% ≥ age 50 yr 34/45 (76%) 125/135 (93%) 0,002
CA 19-9 > 100 3/33 (9%) 91/126 (71%) <0,001
Mean value of S.
IgG4 (range) 550 ± 98,6 (3-
2,890)
69,5 ± 9,4 (3-1,140) <0,001
% with serum IgG4 >
140mg/dL 34/45 (76%) 13/135 (10%) <0,001
% with serum IgG4 >
280 mg/dL 24/45 (53%) 2/135 (1%) <0,001
Multivariate Analyses
of Factors predicting
AIP
Odds Ratio Confidence Interval P Value
IgG4 > 140 mg/dL 37,4 10,6-173,5 <0,001
CA19-9 < 37 11,7 3,70-46,2 <0,001
Ghazele A. et al. 2007
Usefulness of IgG4 in differentiating between pancreatic cancer and autoimmune pancreatitis
Kawa et al., Gastroent., 2007
AUTOIMMUNE PANCREATITIS VS PANCREATIC CANCER - RADIOLOGIC IMAGING
Autoimmune
pancreatitis
Pancreatic
cancer
Complete cutoff of main
pancreatic duct
Uncommon Common
Ductal stricture Multiple Localized (Single)
Upstream duct dilatation Mild Marked
Duct in the mass Present Absent
Diffuse swelling of the pancreas Almost always Rare
Double duct sign Common Common
Kim et al., 2004
Take Home Points
Autoimmune pancreatitis should be considered in patients with refractory pancreatitis without other identifiable etiology
Can present with mass that can be confused with pancreatic carcinoma or lymphoma--patients have been taken for Whipple procedure for this!
Typically responds very well to steroids